EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis

Amit Kumar Singh, Rutuja Gangakhedkar iD, Hemant Singh Thakur, Sunil Kumar Raman, Shripad A Patil, Vikas Jain iD

Microbiology Spectrum · 12.12.2023 · 11 (6)

DOI: 10.1128/spectrum.04597-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 12.12.2023. Verfasst von Amit Kumar Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Animal Facility, ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, M. Miyazaki Marg , Tajganj, Agra, Uttar Pra…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Mycobacteriophages, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research (ICMR), DST | Science and Engineering Research Board (SERB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of antibiotic resistance in Mycobacterium tuberculosis has been the culprit behind the inefficient treatment of tuberculosis (TB). Mycobacteriophages being rapid and specific in their activity against mycobacteria including M. tuberculosis are an emerging alternative solution to the antibiotic resistance problem. D29 mycobacteriophage is known as an efficient lytic phage. Its lytic cassette encodes for two lytic proteins, Lysin A (LysA) and Lysin B (LysB), and a holin protein responsible for the translocation of the former two. LysB is a mycolyl-arabinogalactan esterase, which has shown a promising lytic effect on M. tuberculosis . In this study, we explored the lytic efficiency of D29 mycobacteriophage LysB protein on drug-resistant strains of M. tuberculosis . We demonstrate that LysB effectively lyses multi-drug-resistant M. tuberculosis both alone and along with anti-TB drugs. We also report that the surfactant Tween-80, although not vital, potentiates LysB activity. We are able to demonstrate that LysB can eliminate M. tuberculosis residing in mouse macrophages. Thus, by combining our in vitro and ex vivo data, we are able to claim that LysB is a potential phage-derived therapeutic which should undergo pre-clinical and clinical trials. IMPORTANCE To combat the rapidly emerging drug-resistant M. tuberculosis , it is now essential to look for alternative therapeutics. Mycobacteriophages can be considered as efficient therapeutics due to their natural ability to infect and kill mycobacteria including M. tuberculosis . Here, we have exploited the mycolyl-arabinogalactan esterase property of LysB encoded from mycobacteriophage D29. This study is novel in terms of targeting a multi-drug-resistant pathogenic strain of M. tuberculosis with LysB and also examining the combination of anti-TB drugs and LysB. All the experiments include external administration of LysB. Therefore, the remarkable lytic activity of LysB overcomes the difficulty to enter the complex cell envelope of mycobacteria. Targeting the intracellularly located M. tuberculosis by LysB and non-toxicity to macrophages take the process of the development of LysB as a drug one step ahead, and also, the interaction studies with rifampicin and isoniazid will help to form a new treatment regimen against tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisMycobacteriophagesTuberculosis, Multidrug-ResistantHumansCell MembraneCell Wall

Stichwörter der Autor:innen

D29 mycobacteriophageadditive effectantibiotic resistancemycolyl-arabinogalactan esterasephage therapytuberculosis

Autor:innen und Institutionen

  • Experimental Animal Facility, ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, M. Miyazaki Marg , Tajganj, Agra, Uttar Pradesh, India.
  • Microbiology and Molecular Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research , Bhopal, India.
  • Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute , Lucknow, India.

ORCID-Profile: Rutuja Gangakhedkar, Vikas Jain

Förderung

  • Indian Council of Medical Research (ICMR)
  • DST | Science and Engineering Research Board (SERB)

Zitieren

APA

Singh, A. K., Gangakhedkar, R., Thakur, H. S., Raman, S. K., Patil, S. A., & Jain, V. (2023). Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis. Microbiology Spectrum, 11(6). https://doi.org/10.1128/spectrum.04597-22

Vancouver

Singh AK, Gangakhedkar R, Thakur HS, Raman SK, Patil SA, Jain V. Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis. Microbiology Spectrum. 2023;11(6). doi:10.1128/spectrum.04597-22

BibTeX
@article{Singh2023,
  author = {Singh, Amit Kumar and Gangakhedkar, Rutuja and Thakur, Hemant Singh and Raman, Sunil Kumar and Patil, Shripad A and Jain, Vikas},
  title = {Mycobacteriophage D29 Lysin B exhibits promising anti-mycobacterial activity against drug-resistant Mycobacterium tuberculosis},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {6},
  doi = {10.1128/spectrum.04597-22}
}
Kostenlos starten →